In a Monday announcement, navigation-turned-fitness-wearable manufacturer Garmin has revealed that it has made a new addition to its Vivosmart line of activity trackers --- the Vivosmart HR+.
The new Vivosmart HR+ activity tracker announced by Garmin is essentially an upgraded version of the company's Vivosmart HR device launched last fall. The new device notably brings the GPS functionality to the Vivosmart activity tracker lineup.
The newly-launched Vivosmart HR+ activity tracker with GPS is priced at $220; and it is now available now through the Garmin website.
Though most of the capabilities of the new Vivosmart HR+ activity tracker are similar to that of the Vivosmart HR, the addition of GPS gives the device the capability to keep a more accurate track of distance and more effectively plot running routes on a map when the device is linked to the Garmin Connect mobile app.
Other than the noteworthy addition of GPS, the new Vivosmart HR, like its predecessor, comes with a touch-screen display, and includes heart rate monitoring as well as the ability to track calories, distance, steps, and floors climbed.
A proposal has been put forth by a team of Google employees to the Unicode Consortium this week, suggesting the creation of "a new set of emoji that represents a wide range of professions for women and men." Unicode Consortium is a non-profit...
A new study by the Massachusetts Institute of Technology (MIT) has revealed that Istanbul lies...
The Michael J Fox Foundation is aiming to test wearable sensors in smart watches made by Intel's...
China's Dakang Australia has been looking forward to sign a deal to buy Kidman, one of the Australia's biggest beef producers and owner of farm assets. However, the deal could be cancelled as the Australian government said it found that selling...
In January, trade surplus of Germany decreased since plunge in imports was more than a drop in...
Google has officially released its Nexus Security Bulletin for the month of April. The bulletin...
German drugmaker Merck said that its experimental cancer medicine evofosfamidehas failed in the last stage of clinical tests due to which it won't seek regulatory approval for its treatment.
On Monday, Darmstadt, Germany-based Merck said...
On Tuesday, Facebook announced the launch of a new,...
In an announcement made on Monday, Third-ranking US...
Square Enix's 'Final Fantasy: Brave Exvius' role-playing...
© 2011 AustrianTribune - Tribune Online Services. All times CET (GMT + 1.00).